Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese han population

Molecular Carcinogenesis

Volumn 51, Issue SUPPL. 1, 2012, Pages

  Fan, Weiwei ^a   Zhou, Keke ^b,c   Hu, Dezhi ^b   Song, Xiao ^a   Zhao, Yingjie ^a   Chen, Hongyan ^a   Wei, Qingyi ^d   Chen, Gong ^b   Shi, Jinlong ^b   Du, Guhong ^b   Mao, Ying ^b   Lu, Daru ^a,e   Zhou, Liangfu ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Neurosurgery Department   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e FUDAN UNIVERSITY   (China)

Author keywords

Cumulative effect; Genetic susceptibility; Glioma; MMP3; Polymorphism

Indexed keywords

STROMELYSIN;

ADULT; ANGIOGENESIS; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLIOMA; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLIOMA; HAPLOTYPES; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 84867142596     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20842     Document Type: Article

References (50)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108.
3. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
4. Malmer B, Adatto P, Armstrong G, et al. GLIOGENE an International Consortium to Understand Familial Glioma. Cancer Epidemiol Biomarkers Prev 2007; 16: 1730-1734.
5. Liu Y, Shete S, Hosking F, Robertson L, Houlston R, Bondy M. Genetic advances in glioma: Susceptibility genes and networks. Curr Opin Genet Dev 2010; 20: 239-244.
6. Gu J, Liu Y, Kyritsis AP, Bondy ML. Molecular epidemiology of primary brain tumors. Neurotherapeutics 2009; 6: 427-435.
7. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004; 70: 217-228.
8. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362-1378.
9. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-433.
10. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 1999; 19: 267-284.
11. Rooprai HK, Rucklidge GJ, Panou C, Pilkington GJ. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br J Cancer 2000; 82: 52-55.
12. Wick W, Platten M, Weller M. Glioma cell invasion: Regulation of metalloproteinase activity by TGF-beta. J Neurooncol 2001; 53: 177-185.
13. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-5297.
14. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992; 267: 3581-3584.
15. Overall CM. Molecular determinants of metalloproteinase substrate specificity: Matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22: 51-86.
16. Matsuzawa K, Fukuyama K, Dirks PB, et al. Expression of stromelysin 1 in human astrocytoma cell lines. J Neurooncol 1996; 30: 181-188.
17. Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE. Matrix metalloproteinase expression in childhood astrocytomas. Anticancer Res 2000; 20: 3287-3292.
18. Mercapide J, Lopez De Cicco R, Castresana JS, Klein-Szanto AJ. Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines. Int J Cancer 2003; 106: 676-682.
19. Ye S. Polymorphism in matrix metalloproteinase gene promoters: Implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2000; 19: 623-629.
20. Peng B, Cao L, Wang W, et al. Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: A meta-analysis of 50 case-control studies. Mutagenesis 2010; 25: 41-48.
21. Decock J, Paridaens R, Ye S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet 2008; 73: 197-211.
22. Sun T, Gao Y, Tan W, et al. Haplotypes in matrix metalloproteinase gene cluster on chromosome 11q22 contribute to the risk of lung cancer development and progression. Clin Cancer Res 2006; 12: 7009-7017.
23. Skibola CF, Bracci PM, Halperin E, et al. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS ONE 2008; 3: e2816.
24. Beeghly-Fadiel A, Cai Q, Lu W, et al. No association between matrix metalloproteinase-1 or matrix metalloproteinase-3 polymorphisms and breast cancer susceptibility: A report from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1324-1327.
25. Beeghly-Fadiel A, Xiang YB, Deming SL, et al. No association between matrix metalloproteinase (MMP)-1, MMP-3, and MMP-7 SNPs and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18: 1925-1928.
26. Johnatty SE, Beesley J, Chen X, et al. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet 2010; 6: e1001016.
27. Li R, Zhao Y, Fan W, et al. Possible association between polymorphisms of human vascular endothelial growth factor A gene and susceptibility to glioma in a Chinese population. Int J Cancer 2011; 128: 166-175.
28. Jurinke C, van den Boom D, Cantor CR, Koster H. Automated genotyping using the DNA MassArray technology. Methods Mol Biol 2002; 187: 179-192.
29. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.
30. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-723.
31. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-442.
32. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications. Matrix Biol 1997; 15: 535-541.
33. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-1241.
34. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149.
35. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7: 800-808.
36. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
37. Laurent M, Martinerie C, Thibout H, et al. NOVH increases MMP3 expression and cell migration in glioblastoma cells via a PDGFR-alpha-dependent mechanism. FASEB J 2003; 17: 1919-1921.
38. Lee EJ, Kim SY, Hyun JW, Min SW, Kim DH, Kim HS. Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. Chem Biol Interact 2010; 185: 18-24.
39. McCready J, Broaddus WC, Sykes V, Fillmore HL. Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma. Int J Cancer 2005; 117: 781-785.
40. Lu Z, Wang Y, Zhang Q, et al. Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma. Brain Res 2006; 1118: 6-12.
41. Lu Z, Cao Y, Wang Y, et al. Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China. J Neurooncol 2007; 85: 65-73.
42. Malik N, Kumar R, Prasad KN, Kawal P, Srivastava A, Mahapatra AK. Association of matrix metalloproteinase-1 gene polymorphism with glioblastoma multiforme in a northern Indian population. J Neurooncol 2010.
43. Liu Y, Scheurer ME, El-Zein R, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev 2009; 18: 204-214.
44. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 1990; 29: 5783-5789.
45. Lievre A, Milet J, Carayol J, et al. Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 2006; 6: 270.
46. Nan H, Niu T, Hunter DJ, Han J. Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 3551-3557.
47. Hirata H, Okayama N, Naito K, et al. Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma. Carcinogenesis 2004; 25: 2379-2384.
48. Ricketts C, Zeegers MP, Lubinski J, Maher ER. Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS ONE 2009; 4: e6037.
49. Zhou X, Huang J, Chen J, Su S, Chen R, Gu D. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb Haemost 2004; 92: 867-873.
50. Wu N, Lu X, Hua Y, et al. Haplotype analysis of the stromelysin-1 (MMP3) and gelatinase B (MMP9) genes in relation to coronary heart disease. Ann Hum Genet 2009; 73: 404-410.